by Alex Kadhim
In a multicenter study, researchers have initiated a first-in-human phase 1, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, aimed at treating...
by BMJ Journals
Results of a single-site analysis suggest that despite emerging concern over the potential for secondary tumors and T-cell lymphoma following chimeric antigen receptor (CAR) T-cell infusion, such...
by AACR
Chimeric antigen receptor(CAR)-engineered natural killer (NK) cells designed with a CD28 costimulatory domain have superior anti-tumor efficacy and long-term cytotoxicity, research indicates.
by Alex Kadhim
Researchers from the Centre de Recherche Saint-Antoine (CRSA) at Sorbonne Université in France investigated the impact of early recovery of mucosal-associated invariant T (MAIT) cells and...
by NEJM
Results of a single-site analysis suggest that despite emerging concern over the potential for secondary tumors and T-cell lymphoma following chimeric antigen receptor (CAR) T-cell infusion, such...
by Blood Advances
Preliminary data support bridging radiotherapy (BRT) as a pathway to rapid, significant cytoreduction in patients with central nervous system lymphoma (CNSL) before they undergo chimeric antigen...